Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Farglitazar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 20/20 | 1.00 |
| ▸ | PPARA | Q07869 | 6/20 | 1.00 |
| ▸ | PPARD | Q03181 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Farglitazar SCHEMBL14281408 | 1.00 | PPARG (1.00) | PPARGPPARAPPARD | |
| Farglitazar SCHEMBL2208414 | 1.00 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL2787978 | 0.97 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL2785853 | 0.96 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL2786727 | 0.96 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL2786733 | 0.96 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL2787220 | 0.95 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL2787217 | 0.95 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL2786460 | 0.94 | PPARG (0.89) | PPARGPPARAPPARD | |
| Hydrochloric Acid SCHEMBL7711548 | 0.94 | PPARG (0.88) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250082781-A1 | METHODS OF LOWERING BLOOD GLUCOSE AND TREATING TYPE 2 DIABETES BY ACTIVATION OF PDE4D3 | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2025-03-13 | — | — | US | claimed |
| WO-2025011750-A1 | COMPOUND FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | Université Toulouse III - Paul Sabatier (FR) | 2025-01-16 | — | — | WO | claimed |
| US-20240398905-A1 | COMPOSITIONS AND METHOD FOR ADMINISTERING PPARgamma AGONISTS, SURFACTANT PEPTIDES AND PHOSOPHOLIPIDS | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 2024-12-05 | — | — | US | claimed |
| US-11951158-B2 | Compositions and methods for administering PPARγ agonists, surfactant peptides and phospholipids | LINDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER (US) | 2024-04-09 | — | — | US | claimed |
| EP-4294533-A1 | COMPOSITIONS AND METHODS RELATING TO ALOPECIA | Alastin Skincare, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| US-20230390355-A1 | COMPOSITIONS AND METHODS RELATING TO ALOPECIA | ALASTIN Skincare, Inc. (US) | 2023-12-07 | — | — | US | claimed |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | claimed |
| WO-2023129947-A2 | METHODS OF LOWERING BLOOD GLUCOSE AND TREATING TYPE 2 DIABETES BY ACTIVATION OF PDE4D3 | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2023-07-06 | — | — | WO | claimed |
| US-11542309-B2 | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2023-01-03 | — | — | US | claimed |
| EP-1144065-A1 | APPARATUS AND PROCESS FOR PREPARING CRYSTALLINE PARTICLES | GLAXO GROUP LIMITED (GB) | 2001-10-17 | — | — | EP | claimed |
| US-6294580-B1 | FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE | GLAXO WELLCOME INC. | 2001-09-25 | — | — | US | claimed |
| US-6291496-B1 | E.G., WITH OVEREXPRESSSION OF HER-2/NEU OR OVEREXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR, ARE TREATED WITH STRONGLY BINDING PPAR GAMMA LIGANDS. | CORNELL RESEARCH FOUNDATION, INC. | 2001-09-18 | — | — | US | claimed |
| EP-0888317-B1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | EP | claimed |
| WO-2001047555-A1 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF CLASS I FAMILY OF RECEPTOR TYROSINE KINASES | CORNELL RESEARCH FOUNDATION, INC. (US) | 2001-07-05 | — | — | WO | claimed |
| WO-2001003659-A1 | USE OF RAR ANTAGONISTS AS MODULATORS OF HORMONE MEDIATED PROCESSES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2001-01-18 | — | — | WO | claimed |
| WO-2000038811-A1 | APPARATUS AND PROCESS FOR PREPARING CRYSTALLINE PARTICLES | GLAXO GROUP LIMITED (GB) | 2000-07-06 | — | — | WO | claimed |
| JP-2000507216-A | — | — | 2000-06-13 | — | — | JP | claimed |
| EP-0888317-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1999-01-07 | — | — | EP | claimed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082781-A1 | METHODS OF LOWERING BLOOD GLUCOSE AND TREATING TYPE 2 DIABETES BY ACTIVATION OF PDE4D3 | PDE4D, PDE4A, PDE4B | PPARG 129/4885PPARA 210/4885PPARD 312/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | PPARG 567/4885PPARA 787/4885PPARD 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.